# BGB-16673

Source: https://onco.cc/drugs/bgb-16673/  
OnCo record `bgb-16673` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Instead of blocking BTK, this pill destroys it, so it works even when the enzyme has mutated to escape every inhibitor.

## Summary

Chimeric degradation-activating compound recruiting an E3 ligase to BTK. CaDAnCe-101 (phase 1, relapsed CLL/SLL after covalent BTKi, many with BTK mutations): ORR 86% in 66 patients with a manageable profile (fatigue, bruising, diarrhoea, neutropenia), updated at EHA 2026. Phase 3 CaDAnCe-304 (~500 patients) compares BGB-16673 with pirtobrutinib after covalent BTKi. The first BTK degrader in phase 3.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-07
- Modality: Small-molecule BTK degrader (CDAC)
- Mechanism: Heterobifunctional degrader: one end binds BTK (wild-type or C481/T474/L528 mutant), the other recruits an E3 ligase, tagging BTK for proteasomal destruction.
- Dosing: Oral; 200 mg once daily (recommended phase 2 dose), continuous

## Sources

- CaDAnCe-304 design (Blood 2025): https://ashpublications.org/blood/article/146/Supplement%201/5691/550156/CaDAnCe-304-a-phase-3-open-label-randomized-study

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- technologies: [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [BTK (Bruton tyrosine kinase)](https://onco.cc/targets/btk/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)
- trials: [A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies](https://onco.cc/trials/nct05006716/), [A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors](https://onco.cc/trials/nct06970743/), [CaDAnCe-304](https://onco.cc/trials/cadance-304/), [Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader](https://onco.cc/trials/nct05294731/)
- ideas: [BTK degraders to pre-empt resistance in frontline CLL](https://onco.cc/ideas/idea-btk-degrader-frontline/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/)
- pathways: [Ubiquitin-proteasome system & protein homeostasis](https://onco.cc/pathways/ubiquitin-proteasome-system/)

---
JSON: https://onco.cc/api/v1/entities/bgb-16673.json